CMT-3, a chemically modified tetracycline, inhibits bony metastases and delays the development of paraplegia in a rat model of prostate cancer

Ann N Y Acad Sci. 1999 Jun 30:878:678-82. doi: 10.1111/j.1749-6632.1999.tb07760.x.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Administration, Oral
  • Animals
  • Antineoplastic Agents / therapeutic use*
  • Bone Neoplasms / prevention & control*
  • Bone Neoplasms / secondary*
  • Male
  • Paraplegia / etiology
  • Paraplegia / prevention & control*
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / pathology
  • Prostatic Neoplasms / physiopathology
  • Protease Inhibitors / therapeutic use*
  • Rats
  • Tetracyclines / administration & dosage
  • Tetracyclines / therapeutic use*
  • Time Factors

Substances

  • Antineoplastic Agents
  • Protease Inhibitors
  • Tetracyclines
  • tetracycline CMT-3